O. Kirk

The EuroSIDA study: 25 years of scientific achievements

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2019, HIV medicine.

Combination antiretroviral therapy and the risk of myocardial infarction.

O. Kirk, A. d’Arminio Monforte, R. Weber, 2003, The New England journal of medicine.

Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study

O. Kirk, A. Blaxhult, J. Lundgren, 2003, HIV medicine.

Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV‐positive persons: the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) study

O. Kirk, A. d’Arminio Monforte, C. Sabin, 2018, HIV medicine.

Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

A. Mocroft, A. Blaxhult, J. Lundgren, 2018, HIV medicine.

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

A. Mocroft, Esprit study groups, L. Ryom, 2015, PLoS medicine.

Low body weight and type of protease inhibitor predict discontinuation and treatment‐limiting adverse drug reactions among HIV‐infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort

Henrik Nielsen, O. Kirk, J. Lundgren, 2001, HIV medicine.